PV Bulletin

Injunction No. 2026-DM-031-INJ Regarding Ortho Partner Establishment in Montreuil

ANSM issued an injunction for Ortho Partner to implement specific compliance measures.

Primary source: ANSM (France) - News feed

Translated From French

PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.

PV Impact Brief

Urgency: HighConfidence: high

What changed

Ortho Partner is required to establish compliant storage conditions for medical devices and implement a system for managing non-conformities, complaints, vigilance, recalls, and withdrawals within 3 months.

Why it matters

This injunction could significantly impact operational compliance and oversight at the specified facility, ensuring that medical products are stored correctly and that non-conformities are managed effectively.

Action needed

Establish compliant storage conditions for medical devices and set up a non-conformity management system within 3 months.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Inspection Readiness
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Sep 7, 2026

Full briefing

Practical implication

Establish compliant storage conditions for medical devices and set up a non-conformity management system within 3 months.

The ANSM has ordered the establishment of Ortho Partner located in Montreuil to comply with specific requirements concerning the storage conditions of medical devices and to create a system for managing non-conformities. This action must be completed within a period of 3 months.

What changed: Ortho Partner is required to establish compliant storage conditions for medical devices and implement a system for managing non-conformities, complaints, vigilance, recalls, and withdrawals within 3 months.

Why it matters: This injunction could significantly impact operational compliance and oversight at the specified facility, ensuring that medical products are stored correctly and that non-conformities are managed effectively.

Practical implication: Establish compliant storage conditions for medical devices and set up a non-conformity management system within 3 months.

View original source

  • Source: ANSM (France) - News feed
  • Published at source: 2026-09-07T00:00:00.000Z
  • Discovered by monitor: 2026-09-07T21:36:51.572Z

Published from the regulator source ingestion pipeline after PV impact triage.

Related updates for your role

publicEMA · European Union · Updated Sep 7, 2026

Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products

Urgency: High

Ensure all sites listed in marketing authorization applications are ready for inspection upon submission, and adhere to the new timelines for inspection requests and report submissions.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicTGA · Australia · Updated Sep 7, 2026

Deep Heat Extra Strength 100g Cream

Urgency: High

Regulatory Intelligence teams must initiate checks to monitor compliance and management of this recall, ensuring affected lots are removed from distribution.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026Translated From French

Parenteral iron-containing medicinal products - referral

Urgency: High

Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026Translated From French

PRAC 3 September 2026: Starts safety review of injectable iron-containing medicines Image credit: © tadamichi | stock.adobe.com Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026 4 September 20

Urgency: High

Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward